How Can Vaccine Design Be Modified by the Use of Synthetic Sugars?

Streptococcus pneumoniae kills millions of people worldwide. For the subgroup serotype 8, prevalent in the United States and Western Europe, there is no vaccine to date. In this video, PETER H. SEEBERGER explains the approach of his research group to create a synthetic sugar vaccine against this bacterial infection that works in mice. They relied on synthetic chemistry to assemble sugar chains from monomers; the researchers then connected them to a carrier protein and tested whether they were immunogenic – causing an immune response in living organisms – and whether they were protective. Thus they succeeded in creating the vaccine. Their results have inspired further work in the area in the hope of finding a vaccine for humans. On a fundamental level, the researchers also found that the way in which sugars are presented to the immune system matters with respect to immunogenicity and protection. This has strong implications for future vaccine design.

DOI:

https://doi.org/10.21036/LTPUB10402

Max Planck Institute of Colloids and Interfaces

Colloids and interfaces consist of very small or thin structures with linear dimensions between nanometers and micrometers. On the one hand, the possible structures represent a „world of hidden dimensions“. On the other hand, the dynamics and structures of these small entities determine the behavior of much larger systems such as organisms. A more systematic understanding of colloids and interfaces is a prerequisite for many innovations, such as „smart“ drug delivery systems and biomaterials. Such a deeper understanding can only arise from an interdisciplinary approach that combines chemical synthesis and biomimetic materials science with physical analysis and characterization as well as theoretical modelling. The nano- and microstructures that are investigated at the MPICI are built up from special, even smaller molecules, which are using the principle of “self assembly” to construct ordered structures.